Business Description
Cingulate Inc. is a US-based pharmaceutical company focused on developing new treatments for ADHD and anxiety disorders. Its most advanced drug, CTx-1301, is currently in Phase 3 clinical trials for ADHD patients across all age groups, while CTx-2103 is being developed to treat anxiety and CTx-1302 is planned for future clinical testing as an additional ADHD therapy. Founded in 2012 and based in Kansas City, Kansas, the company uses its proprietary drug delivery technology as the foundation for all its products.
